Mission

To identify new trends and methodological challenges in oncology health economics and outcomes research with the intent of supporting education, awareness, and community engagement while working towards the development of recommendations to address them. 

Background

Oncology is one of the most rapidly evolving therapeutic areas with considerable clinical and economic burden. Health economics and outcomes research in oncology is complicated by (1) the diversity of the epidemiology and biology of various tumors, which limits the sample size and long-term follow-up in clinical trials, (2) the rapidly evolving treatment landscapes and variation in national management recommendations, and (3) the complexities of measuring costs and quality of life in patients and caregivers. Therefore, oncology health economics and outcomes research constitutes a unique segment, and our SIG aims to advance clinical and methodological knowledge for proper clinical and economic evaluation of oncology treatments and diagnostic tools.  

Goals

Engage the oncology community to raise awareness of key components in oncology HEOR and recommended practices.

Offer relevant and impactful educational presentations and activities on the latest oncology HEOR topics.

Create a space to support the discussion of methods of statistical analysis and economic evaluation in oncology, and approaches to support timely access of innovative oncology treatments and diagnostic tools.


Manuscript and Reports

  1. Impact of Delayed Patient Access to Cancer Treatment
  2. Evaluating the role of single-arm trials in oncology decision-making: an interview with Sorrel Wolowacz, RTI Health Solutions

Webinars

  1. Impact of Delayed Patient Access to Cancer Treatment
  2. Measuring the Indirect Costs Driving Financial Toxicity in Oncology
  3. Assessing Causal Treatment Effect for Sequenced Oncology Regimens

Presentations

  1. ISPOR 2026: Advancements in Real-World Evidence (RWE) to Accelerate Access in Rare Cancers: Challenges, Methods, and Decision Making
  2. ISPOR 2025: The Evolution of Patient-Reported Outcome (PRO) Collection in Oncology: Will the Need for Multistakeholder Alignment Prevent Improved Patient-Centered Care?
  3. ISPOR Europe 2024: Current Landscape and Future Directions of Structured Expert Elicitation in Healthcare Decision Making
  4. ISPOR Europe 2023: An Effective Drug Is Not Enough: How Do We Improve Access to Molecular Testing to Enable Personalized Treatment in Oncology?
  5. ISPOR Europe 2022: Clinical Evidence for Health Technology Assessment in Oncology, Are We Going Backwards? Where Are We Going With Single-Arm Trials?

Leadership


Chair-Elect

Lixia Yao, PhD

Associate Professor, Temple University
Chalfont, PA, United States

Past Chair

Min-Hua Jen, PhD

Executive Director, Eli Lilly
Uxbridge, LON, United Kingdom

Chair

Shilpi Swami, MA

ConnectHEOR
London, LON, United Kingdom

Operational Lead

Abril Seyahian

Radboudumc-Department for Health Evidence
Nijmegen, GR, Netherlands

Working Groups

Member Engagement



Co-Chairs

Sehouenou Alberic Candide Ahouehome

Evaluator, CIRRIS CIUISS
Québec, QC, Canada

Jagadeswara Rao Earla, MBA, PharmD, PhD

Associate Director, Outcomes Research, Merck & Co. Inc
Rahway, NJ, United States

Haidong Feng

Associate Principal Scientist, Merck
Boston, MA, United States

Ting-An Tai

Lead, HEOR, Astellas Pharma Europe Ltd
Dublin, Ireland

Pratyusha Vadagam, MS

Associate Director, Johnson & Johnson
Warrington, PA, United States

Ami Vyas, MS, MBA, BS, PhD

Associate Professor, The University of Rhode Island
Kingston, RI, United States

Questions or ideas? Please send an email to Oncologysig@ISPOR.org

Join this Special Interest Group

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×